Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer

Laure Garrigue-Antar, Rhonda F. Souza, Vincent F. Vellucci, Stephen J. Meltzer, Michael Reiss

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Cell lines derived from carcinomas of the upper aero-digestive tract are typically refractory to transforming growth factor β-mediated cell cycle arrest. Recently, we reported that the type II transforming growth factor β receptor (TβR-II) gene can be inactivated on the basis of missense mutations in such cell lines. These findings prompted us to investigate the molecular status of the TβR-II gene in primary tumor specimens. Among 21 of 24 evaluable primary esophageal carcinomas, there were 6 cases (28.5%; 95% confidence interval, 11% to 52%) in which TβR-II transcripts were low or undetectable by a reverse transcription PCR assay. In one of these cases, we were able to ascribe the loss of TβR-II gene expression to high-density methylation of promoter sequences. We failed to detect any mutations within the open reading frame of the remaining tumors that expressed TβR-II mRNA. In this relatively small series of cases, loss of TβR-II expression was independent of pathologic tumor stage, histologic subtype, or outcome of patients with esophageal cancer. Thus, loss of expression of the TβR-II gene appears to be the predominant mechanism through which this gene is inactivated in esophageal cancer.

Original languageEnglish (US)
Pages (from-to)263-272
Number of pages10
JournalLaboratory Investigation
Volume75
Issue number2
StatePublished - Aug 1996

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Esophageal Neoplasms
Gene Expression
Genes
Carcinoma
Cell Line
Neoplasms
Missense Mutation
Cell Cycle Checkpoints
Methylation
Open Reading Frames
Reverse Transcription
Gastrointestinal Tract
Confidence Intervals
Polymerase Chain Reaction
Messenger RNA
Mutation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer. / Garrigue-Antar, Laure; Souza, Rhonda F.; Vellucci, Vincent F.; Meltzer, Stephen J.; Reiss, Michael.

In: Laboratory Investigation, Vol. 75, No. 2, 08.1996, p. 263-272.

Research output: Contribution to journalArticle

Garrigue-Antar, L, Souza, RF, Vellucci, VF, Meltzer, SJ & Reiss, M 1996, 'Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer', Laboratory Investigation, vol. 75, no. 2, pp. 263-272.
Garrigue-Antar, Laure ; Souza, Rhonda F. ; Vellucci, Vincent F. ; Meltzer, Stephen J. ; Reiss, Michael. / Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer. In: Laboratory Investigation. 1996 ; Vol. 75, No. 2. pp. 263-272.
@article{74f182013b154ece9cc9bdf2271785b1,
title = "Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer",
abstract = "Cell lines derived from carcinomas of the upper aero-digestive tract are typically refractory to transforming growth factor β-mediated cell cycle arrest. Recently, we reported that the type II transforming growth factor β receptor (TβR-II) gene can be inactivated on the basis of missense mutations in such cell lines. These findings prompted us to investigate the molecular status of the TβR-II gene in primary tumor specimens. Among 21 of 24 evaluable primary esophageal carcinomas, there were 6 cases (28.5{\%}; 95{\%} confidence interval, 11{\%} to 52{\%}) in which TβR-II transcripts were low or undetectable by a reverse transcription PCR assay. In one of these cases, we were able to ascribe the loss of TβR-II gene expression to high-density methylation of promoter sequences. We failed to detect any mutations within the open reading frame of the remaining tumors that expressed TβR-II mRNA. In this relatively small series of cases, loss of TβR-II expression was independent of pathologic tumor stage, histologic subtype, or outcome of patients with esophageal cancer. Thus, loss of expression of the TβR-II gene appears to be the predominant mechanism through which this gene is inactivated in esophageal cancer.",
author = "Laure Garrigue-Antar and Souza, {Rhonda F.} and Vellucci, {Vincent F.} and Meltzer, {Stephen J.} and Michael Reiss",
year = "1996",
month = "8",
language = "English (US)",
volume = "75",
pages = "263--272",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer

AU - Garrigue-Antar, Laure

AU - Souza, Rhonda F.

AU - Vellucci, Vincent F.

AU - Meltzer, Stephen J.

AU - Reiss, Michael

PY - 1996/8

Y1 - 1996/8

N2 - Cell lines derived from carcinomas of the upper aero-digestive tract are typically refractory to transforming growth factor β-mediated cell cycle arrest. Recently, we reported that the type II transforming growth factor β receptor (TβR-II) gene can be inactivated on the basis of missense mutations in such cell lines. These findings prompted us to investigate the molecular status of the TβR-II gene in primary tumor specimens. Among 21 of 24 evaluable primary esophageal carcinomas, there were 6 cases (28.5%; 95% confidence interval, 11% to 52%) in which TβR-II transcripts were low or undetectable by a reverse transcription PCR assay. In one of these cases, we were able to ascribe the loss of TβR-II gene expression to high-density methylation of promoter sequences. We failed to detect any mutations within the open reading frame of the remaining tumors that expressed TβR-II mRNA. In this relatively small series of cases, loss of TβR-II expression was independent of pathologic tumor stage, histologic subtype, or outcome of patients with esophageal cancer. Thus, loss of expression of the TβR-II gene appears to be the predominant mechanism through which this gene is inactivated in esophageal cancer.

AB - Cell lines derived from carcinomas of the upper aero-digestive tract are typically refractory to transforming growth factor β-mediated cell cycle arrest. Recently, we reported that the type II transforming growth factor β receptor (TβR-II) gene can be inactivated on the basis of missense mutations in such cell lines. These findings prompted us to investigate the molecular status of the TβR-II gene in primary tumor specimens. Among 21 of 24 evaluable primary esophageal carcinomas, there were 6 cases (28.5%; 95% confidence interval, 11% to 52%) in which TβR-II transcripts were low or undetectable by a reverse transcription PCR assay. In one of these cases, we were able to ascribe the loss of TβR-II gene expression to high-density methylation of promoter sequences. We failed to detect any mutations within the open reading frame of the remaining tumors that expressed TβR-II mRNA. In this relatively small series of cases, loss of TβR-II expression was independent of pathologic tumor stage, histologic subtype, or outcome of patients with esophageal cancer. Thus, loss of expression of the TβR-II gene appears to be the predominant mechanism through which this gene is inactivated in esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0029762628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029762628&partnerID=8YFLogxK

M3 - Article

C2 - 8765326

AN - SCOPUS:0029762628

VL - 75

SP - 263

EP - 272

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 2

ER -